Volume 1, Issue 1 (Continuously Updated 2021)                   J Mod Family Med 2021, 1(1): 106-106 | Back to browse issues page

XML Persian Abstract Print

Department of Research, School of Nursing, Bank Melli Iran, Tehran, Iran.
Abstract:   (490 Views)
Background: Coronavirus Disease 2019 (COVID-19) pandemic has affected most countries in the world and there is no specific treatment for this disease. Therefore, finding the right treatment for improving the patients’ conditions is essential. 
Objective: This study aims to evaluate the effect of jujube tea on peripheral blood count of patients with COVID-19.
Methods: This is a before-after clinical trial conducted on 50 patients with COVID-19 hospitalized in Bank Melli Iran Hospital in Tehran, Iran, who were selected using a purposive sampling method. Patients consumed jujube tea twice a day for two weeks in addition to conventional medication therapy. Their demographic information were recorded and laboratory test measuring their C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR), Lymphocytes, Neutrophils, White Blood Count (WBC), Monocytes, and Eosinophils were conducted before and after the intervention. The collected data were analyzed in SPSS v.22 software. Significance level was set at P<0.05.
Findings: The mean age of patients was 60.26‌±‌14.53. After the intervention, a significant difference was observed in WBC (P<0.001), eosinophil (P<0.‌004) monocyte (P<0.035), and CRP (P<0.001) levels compared to the pre-intervention values. Patients with underlying disease had a significant difference in WBC, monocyte and CRP levels compared to the pre-intervention values (P<0.05).
Conclusion: Jujube tea may be effective in improving the immune function of patients with COVID-19. Therefore, it is recommended to use jujube as a supportive treatment along with chemical drugs.
Full-Text [PDF 3710 kb]   (246 Downloads) |   |   Full-Text (HTML)  (309 Views)  
Type of Study: Research |
Received: 2021/02/21 | Accepted: 2021/05/15 | Published: 2021/06/20

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.